Danish Pharmacovigilance Update, 26 September 2013

In this issue of Danish Pharmacovigilance Update:

News from the EU

• Filgrastim (Neupogen) and pegfilgrastim (Neulasta) are associated with risk of capillary leak syndrome
• Use of bromocriptine (Parlodel®) for prevention or suppression of lactation is to be reassessed
• Pregnancy prevention programme during treatment with Erivedge
• Risk of hypermagnesaemia from the use of the parenteral nutrition preparations Numeta G13E and G16E
• Be aware of the bleeding risk factors associated with the use of the new oral anticoagulants Eliquis®, Pradaxa® and Xarelto®
• Lariam® and neuropsychiatric adverse reactions
• Use of short-acting beta-agonists for obstetric indications

News from the Danish Health and Medicines Authority

• Psychotic or manic symptoms emerging during use of methylphenidate and atomoxetine
• Adverse reaction reports concerning the HPV vaccine from 1 January through 9 September 2013